Log in
Enquire now
‌

US Patent 10941400 Compounds and methods for enhanced cellular uptake

Patent 10941400 was granted and assigned to Regulus Therapeutics on March, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Regulus Therapeutics
Regulus Therapeutics
0
Current Assignee
Regulus Therapeutics
Regulus Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
109414000
Patent Inventor Names
Balkrishen Bhat0
Date of Patent
March 9, 2021
0
Patent Application Number
162505290
Date Filed
January 17, 2019
0
Patent Citations
‌
US Patent 10150967 MicroRNA compounds and methods for modulating miR-122
Patent Citations Received
‌
US Patent 12005120 Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
0
Patent Primary Examiner
‌
Lawrence E Crane
0
Patent abstract

Described herein are conjugated modified oligonucleotides that are complementary to a target RNA. The conjugate facilitates cellular uptake of the modified oligonucleotide, resulting improved potency.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10941400 Compounds and methods for enhanced cellular uptake

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.